Current Headlines

  1. Alpha Cognition Announces Partner China Medical System Has NDA Accepted In China For The Review Of ZUNVEYL (Benzgalantamine) For Alzheimer's Disease 7/29/2025

    Alpha Cognition Inc. (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer’s dementia.

  2. Transforming Drug Development With Groundbreaking Organ-On-Chip Tech 7/29/2025

    An international team of researchers supported by the EU-funded UNLOOC(opens in new window) project is developing organ-on-chip (OOC) systems that simulate human organ responses, providing faster, safer and more reliable drug testing alternatives.

  3. SLAS Discovery: Advancing Tools For Cancer Fibrosis And Drug Discovery 7/29/2025

    Volume 34 of SLAS Discovery includes two original research articles, one short communication and one entry in the upcoming Special Issue on EUOS/SLAS Joint Challenge: Compound Solubility.

  4. Making Medicine Out Of Millipedes 7/29/2025

    Millipedes get a bad rap — their many legs put people off and could classify them as “creepy crawly.” But these anthropods’ secretions could hold the key to new drug discovery for the treatment of neurological diseases and pain.

  5. Astrocytes Identified As Hidden Culprit Behind PTSD 7/29/2025

    Did you know that patients with post traumatic stress disorder (PTSD) often struggle to forget traumatic memories, even long after the danger has passed? This failure to extinguish fear memories has long puzzled scientists and posed a major hurdle for treatment, especially since current medications targeting serotonin receptors offer limited relief for only a subset of patients.

  6. GSK And Hengrui Pharma Enter Agreements To Develop Up To 12 Innovative Medicines Across Respiratory, Immunology & Inflammation And Oncology 7/28/2025

    GSK plc today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031.

  7. LENZ Therapeutics Announces NMPA Submission Of New Drug Application For LNZ100 In China For The Treatment Of Presbyopia 7/28/2025

    LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that CORXEL Pharmaceuticals (“CORXEL”) has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC).

  8. Kling Bio Announces Collaboration With Sanofi For Accelerated Discovery Of Neutralizing Antibodies 7/24/2025

     Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its groundbreaking B cell immortalization and screening platform, Kling-Select.

  9. Precision BioSciences Receives FDA Orphan Drug Designation For PBGENE-DMD For The Treatment Of Duchenne Muscular Dystrophy 7/23/2025

    Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

  10. Bavarian Nordic Receives Acceptance From Health Canada For Review Of The New Drug Submission For Its Chikungunya Vaccine 7/22/2025

    Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.